Tiziana Life Sciences (NASDAQ: TLSA) Building Momentum: Patience Could Pay Off Big 🤑
Published: Fri, 02/14/25
Updated: Fri, 02/14/25
Get the Full Story - Breaking News Released! Download our Mobile App📱
SPONSORED
.
Tiziana Life Sciences (NASDAQ: TLSA) Building Momentum: Patience Could Pay Off Big 🤑
Tiziana Life Sciences Ltd.
(NASDAQ: $TLSA)
===========================
Alert Price - $0.745 per share
Market Cap - $81.23M
Avg. Volume - $184,039
Members,
Since our initial alert on, Tiziana Life Sciences Ltd (NASDAQ: TLSA) has been gaining traction, currently trading at $0.745 (+0.62%) with a 24-hour trading volume of 182,634. Over the past 52 weeks, TLSA has surged +40.55%, reflecting growing investor confidence in its breakthrough therapies.
With momentum steadily building and increasing market interest, we expect more upside heading into next week. As TLSA continues to push forward in the biotech space, this could be a pivotal moment for the stock. With a pipeline of cutting-edge therapies targeting some of the most challenging diseases, NASDAQ: TLSA could
be on the verge of a game-changing breakout.
We believe NASDAQ: TLSA is still going to be a boomer trade with a 85% surge in sight, offering a compelling short-term setup while holding long-term potential as a major player in the biotech space.
Watch Recent milestone here:
Technical Overview
Tiziana Life Sciences Ltd (NASDAQ: TLSA) is gradually gaining momentum, currently up 0.62% with a 24-hour trading volume of 182,634, indicating increasing investor interest. The stock has shown strong resilience, surging +40.55% over the last 52 weeks, a testament to its growing market confidence.
From a technical
standpoint, TLSA’s double bottom formation around $0.63 remains a key bullish indicator, often preceding major breakouts. With an RSI of 50.89, the stock has ample room for upward movement, and trading below key moving averages suggests potential for a strong reversal as momentum builds. If this trend continues, TLSA could be on the verge of a significant breakout, making patience and strategic positioning crucial.
Given these technical alignments, NASDAQ: TLSA is still setting up for an 85% surge, offering traders a strategic opportunity to capitalize on its momentum before the breakout fully unfolds.
TLSA’s Breakthrough in Immunotherapy
Beyond the
technicals, TLSA’s remain a strong driving force behind its potential breakout. The company’s groundbreaking work in neuroinflammatory and neurodegenerative diseases, particularly its lead candidate Foralumab (TZLS-401) for Alzheimer’s, Multiple Sclerosis, and ALS, positions it at the forefront of next-generation immunotherapies.
Additionally, Tiziana Life Sciences has maintained a lean operational model, focusing resources on drug discovery while leveraging expert teams to accelerate development. With a patent application for Foralumab’s use in CAR-T
therapy, TLSA is not just advancing treatment options but also expanding its market potential in the broader biotech sector.
With these strong fundamentals aligning with bullish technical patterns, TLSA’s momentum could be just getting started.
About Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a United Kingdom-based biotechnology company, founded in 2013, that focuses on groundbreaking treatments in immunology and oncology. The company went
public on March 24, 2000, and operates within the healthcare sector, specializing in cutting-edge biotech advancements. Despite having a lean team of just nine employees, Tiziana is making significant strides under the leadership of CEO Ivor Elrifi.
Its lead product candidate, Foralumab (TZLS-401), is the first and only fully
human anti-CD3 monoclonal antibody, showing immense potential in treating multiple sclerosis, Crohn’s disease, ulcerative colitis, and other inflammatory conditions.
Headquartered in London, Tiziana Life Sciences Ltd. continues to push the boundaries of biotech innovation, positioning itself as a key player in the fight against autoimmune diseases and
cancer.
Under the leadership of CEO Ivor Elrifi, Tiziana Life Sciences has positioned itself as a high-growth biotech disruptor with the
potential to redefine how immune-based diseases are treated. With a strong research pipeline, strategic innovation in immunotherapy, and a commitment to delivering life-changing treatments, TLSA is not just another biotech stock—it’s a pioneer in the next era of medical breakthroughs.
Tiziana Life Sciences (NASDAQ: TLSA) - Key Metrics
Total Valuation - Market Cap:
$80.72M - Enterprise Value $79.77M
Tiziana Life Sciences (NASDAQ: TLSA) has a market cap or net worth of $80.72 million as of February 14, 2025. Its market cap has increased by a staggering 46.32% in one year.
Important Dates - Next Earnings Date: February 25, 2025 (Before Market Open)
ThinkEquity Firm analyst Ashok Kumarhas a "strong buy" ratings on TLSA stock with a $4 price target and a +440.54% price uptick.
Why Now is the Time to Consider Tiziana Life Sciences (NASDAQ: TLSA)
Tiziana Life Sciences (TLSA) presents a compelling opportunity at its current levels, backed by strong technical indicators and groundbreaking advancements in neurodegenerative disease treatments. The stock is showing a double bottom formation near $0.63, a classic bullish reversal pattern that historically precedes major upward moves.
With the RSI at 50.89, TLSA is neither overbought nor oversold, signaling ample room for an upside breakout. Additionally, it's trading below its moving averages, a setup that often allows for high-percentage gains when momentum kicks in—setting the stage for a potential 85% surge.
Beyond technicals, the company is spearheading the next generation of immunotherapies, with Foralumab (TZLS-401) being the only fully human anti-CD3 monoclonal antibody under development.
Its potential to revolutionize treatment for Alzheimer’s, Multiple Sclerosis, and ALS makes TLSA a standout player in the biotech sector. As the demand for effective therapies skyrockets, this stock could be primed for significant revaluation.
With institutional interest growing, and a breakthrough in a
multi-billion-dollar industry, TLSA is an opportunistic trade with a long-term growth narrative—a rare biotech play that could deliver exponential returns.
Don’t miss out—Tiziana Life Sciences (NASDAQ: TLSA) is about to explode in value, and this is your chance to get in early!
As always, we encourage you to conduct your own research and consider how Tiziana Life Sciences (NASDAQ: TLSA) fits into your broader investment strategy.
This newsletter is a Paid Advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by DEXWireNews LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to DEXWireNews LLC.
You are reading this
newsletter because you have subscribed via our opt-In signup form on our website. If you have been subscribed by accident, then you may unsubscribe by clicking the link below.
By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or
licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research
and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our
website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be
based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here: We do NOT own shares of any of the companies mentioned herewithin, nor intend to buy any in the future.
You should read and review, if and to the extent available, any information concerning an advertised company available at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at http://www.sec.gov and the Financial Industry Regulatory Authority (the "FINRA") at http://www.FINRA.org. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud
at https://www.sec.gov/reportspubs/investor-publications/investorpubscyberfraudhtm.html, as well as related information published on how to invest carefully. You are responsible for verifying all claims and conducting your own
due diligence. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertised company, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, advertising, opinions, products or other materials on external sites or
information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. You also acknowledge that we are not an investment advisory
service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertised company.
Our business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars electronically via bank wire by One
Eyed Jack Enterprises LLC for an advertising / marketing campaign for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA) beginning on 2/13/2025 and ending on 2/20/2025. DEXWireNews may receive additional campaigns in the future by One Eyed Jack Enterprises LLC to distribute media for Tiziana Life Sciences Ltd. (NASDAQ: $TLSA).
Any
compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely
for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may
contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not
been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, we often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are
double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change
at any time without notice.
Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at
different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if they receive the Information later than other investors? If the trading volume and price of a Profile Issuer’s securities increases after the Information is provided to an earlier group of investors, then subsequent investors will pay inflated prices for any securities of the Profiled Issuers that they purchase. This will likely result in the Profiled Issuers having trading losses.